Contact Us  
Hermes
 
 
 

HERMES MILESTONES

2007
bullet Hermes enters into collaborative agreements with CHDI, Inc. to develop targeted lipidic nanocarriers of small molecules and nucleic acid therapeutics for the treatment of Huntington’s disease. The agreements provide up to $1.29M of research funding to Hermes.
bullet Clinical Trials Application (CTA) is filed in Europe for a randomized Phase II clinical trial comparing Nanoliposomal CPT-11 (HBI-202, PEP02) with irinotecan or docetaxel in gastric cancer patients. 
bullet Investigational New Drug (IND) application is filed with the United States FDA for a Phase I clinical trial of Nanoliposomal Irinotecan (HBI-202) in patients with malignant gliomas at the University of California at San Francisco (UCSF)
2006  
bullet PharmaEngine completes the Phase I trial of Nanoliposomal CPT-11 (PEP02) in Taiwan and intiates a Phase I/II clinical trial for Nanoliposomal CPT-11 (HBI-202, PEP02) in combination with cisplatin in patients with cervical cancer in Taiwan.
bullet TLC initiates Phase II clinical trial for Nanoliposomal vinorelbine (NanoVNB) in Taiwan.
bullet HERMES holds preIND meeting with the United States FDA for an IND filing in connection with Phase I/II trial of Nanoliposomal CPT-11 (HBI-202) in Patients with Malignant Gliomas in the U.S.
2005  
bullet HERMES exclusively licenses patents covering novel gene delivery compositions and methods (GenospheresTM) and liposome diagnostics technologies developed by the members of the Liposome Research Laboratory at the California Pacific Medical Center (CPMC) in San Francisco.
bullet HERMES expands its strategic partnership with PharmaEngine for the development of Nanoliposomal CPT-11 (HBI-202, PEP02) in Europe.
bullet Initiation of Phase I clinical trial for the second clinical candidate, Nanoliposomal CPT-11 (HBI-202, PEP02) in Taiwan by a second Asian partner, PharmaEngine, Inc.
2004  
bullet Dr. Keelung Hong and Mr. George Yeh leave their management positions with HERMES Biosciences to concentrate on the Asian Development of Nanoliposomal Vinorelbine at TLC
bullet HERMES and CaRA announce the finalization of their merger. Dr. Andrew Bradbury becomes a scientific advisor to HERMES.
bullet HERMES announces the filing of an IND in Taiwan and initiation of Phase I clinical trial for its first clinical candidate, liposomal vinorelbine (NanoVNB) by its partner, Taiwan Liposome Company (TLC)
2003  
bullet HERMES IP includes nine issued U.S. patents covering trademark S.M.A.R.T. Immunoliposome and Genosphere technologies, as well as a number of other patents pending.
bullet HERMES and CaRA announce their intent of merging CaRA into HERMES.
bullet HERMES becomes the Liposome Pharmacology Core for the NIH-funded Program Project "Mechanism-based evaluations of ErbB targeted agents" at the University of California Cancer Center, University of California  San Francisco.
bullet HERMES enters into a strategic partnership with Taiwan Liposome Company (TLC), a biotechnology company involved in drug delivery that has developed several liposomal therapeutics. The agreement involves co-development of novel therapeutics based on HERMES technologies for important medical needs in Asia.
bullet Mr. George Yeh joins HERMES management team as VP-Finance & Administration. Dr. Raynomd Pooh, Ph.D., joins HERMES management as VP-Corporate Development.
2002  
bullet HERMES continues its unique industry-academic partnership with UCSF Comprehensive Cancer Center investigators for five more years with successful recompetition of the UCSF Breast SPORE (Specialized Program of Research Excellence) and the newly awarded UCSF Brain SPORE. NCI/SPORE (P50) funding is awarded to the most highly competitive academic institutions for rapid translational development of promising and innovative anticancer therapeutics. HERMES S.M.A.R.T. Immunoliposomes thus become the foundation technology for two major therapeutic projects within the UCSF Breast and Brain SPOREs.
bullet HERMES is awarded a three-year $2.3M Unconventional Innovations Program (UIP) contract from NCI to extend its proprietary immunoliposome platform technology toward development of tumor-targeted and internalizing imaging probes and novel therapeutic agents.
2001  
bullet HERMES’ lead agent, anti-HER2 immunoliposomes, enters GMP production in conjunction with the NCI Biological Resources Branch.
bullet US Patents Nos. 6,210,707 and 6,214,388 are issued for University of California inventions, licensed exclusively to HERMES, on immunoliposome conjugation and immunoliposome internalization.
bullet HERMES secures ownership rights for novel drug hydrosol technology (US Patent No. 6,048,550).
bullet HERMES enters into partnership with CaRA (California Recombinant Antibodies, Inc.), a biotechnology company founded by Drs. James Marks and Andrew Bradbury, for joint discovery of novel scFvs for targeted drug delivery.
bullet HERMES enters into partnership with TTY, an Asian pharmaceutical company, for research and co-development of new liposome drugs. Research funding is also contributed by the Republic of China government in Taiwan.
bullet HERMES enters into a licensing and development partnership with Alza/Johnson&Johnson. The partnership involves co- development of HERMES S.M.A.R.T. Immunoliposome technology directed against HER2 in conjunction with liposomal doxorubicin. Terms of the agreement include significant royalties on net sales, as well as upfront payment, research funding, milestone payments, and license maintenance fees.
bullet HERMES enters into a research collaboration with Glaxo-SmithKline (GSK). The partnership involves joint research of HERMES S.M.A.R.T. Immunoliposome technology in conjunction with an antibody and drug provided by GSK as well as HERMES’ antibodies and drugs.
2000  
bullet US Patent No. 6,071,533 is issued to the University of California and licensed exclusively to HERMES on stable formulations of nucleic acid-liposome complexes for efficient in vivo gene delivery.
bullet HERMES exclusively licenses key intellectual property from the University of California developed by UCSF investigators/HERMES founders. The IP relates to immunoliposome conjugation, immunoliposome internalization, antibody screening, and specific antibodies.
bullet HERMES is awarded an expanded SBIR (FLAIR award) from NCI for research involving novel small molecules to be delivered by HERMES liposome and immunoliposome technologies.
bullet HERMES moves to new facilities at South San Francisco, CA, which include offices and laboratories.
1999  
bullet

HERMES completes Series A financing from a group of private investors
bullet

US. Patents Nos. 5,980,935 (1999) and 6,110,491 (2000) are issued to HERMES for novel lipid-based nucleic acid delivery vectors and novel methods for drug loading into liposomes.
1998  
bullet UCSF investigators - HERMES founders receive NCI sponsorship for clinical development of anti-HER2 immunoliposomes (NSC 7013315) under the NCI Decision Network.
bullet HERMES enters into a Research and Option Agreement with the Liposome Research Laboratory, California Pacific Medical Center, giving HERMES the first option to commercialize the drug and gene delivery technologies developed in the Laboratory over the next 5 years.
bullet Hermes Biosciences, Inc. (HERMES) is founded by Drs. Demetrios Papahadjopoulos, Keelung Hong, Dmitri B. Kirpotin, John W. Park, Christopher C. Benz, and James D. Marks.
 
 

Hermes Biosciences • 61 Airport Blvd., Suite D., South San Francisco, CA 94080 • 650-873-2583